Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

• Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

  Business - MarketWatch - October 30

• How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS

  Business - CNBC - 5 days ago
• 

  Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

  Business - Financial Times - October 30

• Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

  Business - CNBC - October 30

• Honeywell’s stock falls as sales miss and lowered guidance offsets profit beat

  Business - MarketWatch - October 24

More from CNBC

• Target's recent trade imports data tells the real story behind massive earnings miss

  Business - CNBC - 11 minutes ago

• Bitcoin hits fresh record, races toward $100,000 as rally continues

  Business - CNBC - 11 minutes ago

• Trump and Fed Chair Powell could be set on a collision course over interest rates

  Business - CNBC - 1 hour ago

• Nvidia says it will sell more of its next-generation Blackwell chips than previously anticipated

  Business - CNBC - 13 hours ago

• CFPB expands oversight of digital payments services including Apple Pay, Cash App, PayPal and Zelle

  Business - CNBC - 3 minutes ago